BPC-157 — identity, handling and published literature

A synthetic 15-amino-acid sequence derived from a fragment of the human gastric protein BPC. Supplied as 10 mg lyophilised powder for laboratory research use.

Presentation and physical properties

Reconstitution arithmetic for this vial

The arithmetic is a single division:

concentration (mg/mL) = vial mass (mg) ÷ diluent volume (mL)

Worked below for this vial, which contains 10 mg. The right-hand column converts to the U-100 scale, on which one graduation is 0.01 mL.

Dissolution of a lyophilised cake is normally carried out by directing the diluent against the vial wall rather than onto the cake, and by allowing the solid to dissolve without shaking, since mechanical agitation promotes the aggregation described under Storage and stability.

The reconstitution calculator performs the same division for other volumes and vial masses. It fills in vial strength only. It does not hold a target amount for any compound, and neither does this page: the volume is ours to calculate, the target amount is not.

Storage and stability

Sealed lyophilised solid

The freeze-dried solid is the stable form. It is normally held at −20 °C or below, sealed and desiccated, protected from light and from atmospheric moisture. Short periods at 2–8 °C or at ambient temperature during transit do not affect lyophilised material. Vials are commonly allowed to reach room temperature before opening, so that atmospheric water does not condense onto cold solid.

In solution

Once a lyophilised peptide is taken into aqueous solution, its degradation rate rises by orders of magnitude relative to the solid state. Solutions are held refrigerated at 2–8 °C and protected from light. Repeated freeze-thaw cycling of solutions is avoided in laboratory practice because it promotes aggregation.

Documented degradation routes

The principal chemical degradation routes documented for peptides in the solid and solution state are asparagine and glutamine deamidation, aspartate-mediated backbone hydrolysis, methionine and cysteine oxidation, and physical aggregation. Solid-state deamidation kinetics and the influence of excipients and residual water are described by Li and colleagues (2005) and by DeHart and Anderson (2012) [7, 8]. Two of these routes are not available to this sequence, which carries neither methionine nor cysteine; the aspartate-mediated route is, given the Asp-Asp-Ala motif.

The 28-day convention

The 28-day figure commonly applied to a reconstituted vial that is entered more than once is a property of the preservative system in the diluent, not of the peptide. It describes the period over which a preserved aqueous vehicle is conventionally treated as still meeting its antimicrobial specification after first entry. It is not a stability statement about this compound, and no stability-indicating study specific to this material is cited here.

Analytical identity and certificate literacy

Routine characterisation of this peptide in the published literature and on supplier certificates is reversed-phase HPLC for purity and electrospray or MALDI-TOF mass spectrometry for identity confirmation against the expected average mass.

What area-percent purity does and does not measure

An area-percent purity figure is the proportion of detector response attributable to the main peak, under one chromatographic method, at one detection wavelength. It measures the separation achieved by that method. It does not measure counter-ion content, residual water, residual synthesis solvents, endotoxin, sterility, or the identity of the main peak — identity is what the mass spectrometry result establishes, which is why the two tests are reported together and neither substitutes for the other.

What net peptide content means

Net peptide content is the proportion of the weighed mass that is peptide, the remainder being counter-ion — acetate, here — and residual water. It is a separate number from purity and is determined separately, typically by nitrogen determination or amino acid analysis. A material can be high in chromatographic purity and still carry a substantial non-peptide mass fraction, and the two figures answer different questions.

What lot-to-certificate traceability means

Traceability means that a certificate of analysis identifies the specific manufacturing lot it was issued against, and that the vial can be tied back to that lot through the supply record. A certificate that names no lot describes some material, not this material.

What the published literature investigated

Studies are grouped by the model in which the work was done. Each line states what was investigated, in what model, and what the authors reported. No conclusion is drawn across studies.

In vitro

• Chang and colleagues (2011) investigated whether the pentadecapeptide affected tendon fibroblast outgrowth, survival and migration, in cultured rat Achilles tendon fibroblasts and tendon explants, and reported increased fibroblast outgrowth from explants and increased cell survival and migration in the treated cultures relative to control, associating the migration effect with the FAK-paxillin pathway. [1]
• Chang and colleagues (2014) investigated growth hormone receptor expression, in cultured rat Achilles tendon fibroblasts, and reported increased growth hormone receptor expression in the treated fibroblasts, proposing this as a mechanism contributing to the proliferative effects observed in their earlier work. [2]

Rodent models

• Biçer and colleagues (2026) investigated a head-to-head histopathological and biomechanical comparison of BPC-157, TB-500 and the two in combination following standardised Achilles tendon transection and repair, in 32 male Sprague-Dawley rats in four groups of eight (control, BPC-157, TB-500, combination) assessed over four weeks post-operatively, and reported significantly higher maximum load to failure in the TB-500 group than control and significantly lower total Movin scores in the TB-500 and combination groups. The authors reported that the combination provided no additional benefit over the single agents, and suggested the two may converge on shared downstream pathways. [3]

Non-rodent animal models

No non-rodent animal study is included in the reference set for this entry.

Human tissue, ex vivo

• Yildirim and colleagues (2026) investigated whether the peptide produced vasorelaxation in isolated human arterial tissue and whether any such effect was endothelium-dependent, in internal mammary artery rings (n = 12) obtained during coronary artery bypass graft surgery and prepared both endothelium-intact and endothelium-denuded, and reported a concentration-dependent reduction in phenylephrine-induced contraction that was significantly greater in endothelium-intact rings, with nitric oxide synthase inhibition substantially reducing the response; the authors concluded the effect was predominantly endothelium-dependent and nitric-oxide mediated. [4]

Human studies

No published, peer-reviewed randomised controlled trial is available for any indication. See Evidence gaps and limitations.

Review articles and secondary sources

• Sikiric and colleagues (2020) published a review article placing the pentadecapeptide within a cytoprotection and adaptive cytoprotection framework, synthesising the authors’ own predominantly rodent preclinical programme, and set out their proposed framework. As a narrative review by the originating research group, it is a secondary source and is not independent replication. [5]
• Mendias and Awan (2026) published a narrative review of the evidence base for twelve approved and unapproved peptides used in musculoskeletal and athletic contexts — including BPC-157, TB-500, thymosin β4, GHK-Cu, CJC-1295, ipamorelin, MOTS-c, SS-31, tesamorelin, sermorelin, AOD-9604 and FS-344 — and reported that while many of these unapproved peptides show favourable tissue-repair and metabolic outcomes in animal models, rigorous human safety data are scarce, identifying this as an evidence gap with potential for harm. [6]

Evidence gaps and limitations

This section states what the literature does not establish. It is the most decision-relevant part of the entry.

• No randomised controlled trial. There is no published, peer-reviewed randomised controlled trial of BPC-157 for any indication. This is the single most important statement on this page.
• Unavailable and withdrawn data. Two industry-sponsored clinical trials referred to in the literature do not appear in any major trials database, and a 2015 registered trial had its data withdrawn before external review.
• Small, uncontrolled human literature. Case series exist, with between 2 and 16 participants and no comparison groups. A series without a comparison group cannot separate an effect from the course of the condition being observed.
• Concentration of authorship and undisclosed conflicts. Nearly the entire literature is authored by a single research group. An investigation by Undark, published by STAT News in February 2026 reported that the group’s lead author owns a company holding a BPC-157 patent offered for sale, and that these conflicts were not disclosed on the published papers. [9]
• No toxicology to regulatory standard. No acute-toxicity, repeat-dose, genotoxicity, reproductive-toxicity or carcinogenicity studies to regulatory standard have been identified by the FDA in its bulk-substance review. [10]
• No systematic human safety dataset. No systematically collected human adverse-event dataset exists for this compound. Absence of recorded events is not evidence of an absence of events; it is an absence of data collection.
• Effect sizes not established. Effect sizes in humans are not established for any purpose.
• Mechanism is proposed, not demonstrated in humans. The angiogenic and nitric-oxide-related mechanisms described in the preclinical literature are proposals advanced by the investigating groups. They have not been confirmed in controlled human work.

Regulatory and standards position

Laboratory handling and safety

No harmonised classification and labelling entry exists for this substance under the CLP Regulation as retained in UK law. In the absence of a harmonised entry and of a toxicological dataset to regulatory standard, the material is handled as a substance of unknown toxicity, and the controls below are the ordinary ones for a synthetic peptide solid whose toxicology has not been characterised.

• Personal protective equipment. Laboratory coat, nitrile gloves and eye protection. Gloves are changed on contamination and removed before handling shared surfaces.
• Weighing and transfer. Lyophilised material is light and readily raised as dust. Transfers are made without generating dust, and where local rules require, in a ventilated enclosure.
• Solutions. Containers are labelled with the substance, the concentration, the diluent and the date of preparation. An unlabelled solution is unidentifiable once the cake has gone.
• Spills. Solid is collected without dispersing it, the surface is decontaminated, and the residue is treated as chemical waste. Solutions are absorbed and the area cleaned.
• Disposal. Disposed of as chemical waste in accordance with local regulations and the institution’s waste procedures. Not disposed of to drain.
• Reject criteria. A damaged seal, a collapsed or discoloured cake, liquid present in a sealed vial, or a vial that cannot be tied to a certificate of analysis are grounds for rejecting the vial rather than dissolving it.

Related compounds and consumables

• TB-500 — library entry, the other single compound in this catalogue category, and the comparator in reference 3
• All compound library entries
• Recovery & Regeneration — catalogue category
• Bacteriostatic water — preserved aqueous diluent
• Sterile water — unpreserved aqueous diluent
• Reconstitution calculator

References

1. Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (1985). 2011;110(3):774–80. Model: in vitro, cultured rat Achilles tendon fibroblasts and tendon explants. PMID: 21030672. PubMed
2. Chang CH, Tsai WC, Hsu YH, Pang JH. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066–77. Model: in vitro, cultured rat Achilles tendon fibroblasts. PMID: 25415472. PubMed
3. Biçer O, Adanir O, Güleryüz Y, Balci EC, Dinçel YM, Yenigün MY, Aydin C, Bayrak BY. Jt Dis Relat Surg. 2026;37(3):822–837. Model: rodent, 32 male Sprague-Dawley rats in four groups of eight, four weeks post-operatively. PMID: 42542926. PubMed
4. Yildirim AK, Dastan AO, Demeli Ertus M, Ensarioglu M, Karabacak K, Pehlivanoglu B. J Clin Med. 2026;15(9):3488. Model: ex vivo human tissue, internal mammary artery rings (n = 12), endothelium-intact and endothelium-denuded. PMID: 42123221. PubMed
5. Sikiric P, Hahm KB, Blagaic AB, et al. Stable Gastric Pentadecapeptide BPC 157, Robert’s Stomach Cytoprotection/Adaptive Cytoprotection/Organoprotection, and Selye’s Stress Coping Response: Progress, Achievements, and the Future. Gut Liver. 2020;14(2):153–167. Model: narrative review synthesising the authors’ own predominantly rodent preclinical programme. PMID: 31158953. PubMed
6. Mendias CL, Awan TM. Sports Med. 2026 Apr 12 [Epub ahead of print]. Model: narrative review of the published human and animal literature on twelve approved and unapproved peptides. PMID: 41966639. DOI: 10.1007/s40279-026-02437-0. PubMed
7. Li B, et al. J Pharm Sci. 2005;94(8):1723–35. Model: solid-state peptide degradation kinetics; general peptide stability, not compound-specific. PMID: 15986465. PubMed
8. DeHart MP, Anderson BD. J Pharm Sci. 2012;101(9):3142–56. Model: solid-state peptide degradation; general peptide stability, not compound-specific. PMID: 22437444. PubMed
9. Undark investigation carried by STAT News, February 2026. Source type: investigative journalism reporting on the research record and authorship conflicts. statnews.com
10. US Food and Drug Administration. Certain bulk drug substances for use in compounding may present significant safety risks. Source type: regulatory listing and review material. fda.gov
11. National Center for Biotechnology Information. PubChem Compound Summary for CID 9941957. Source type: chemical registry record; sequence, formula, average mass, CAS number and synonym list. PubChem

Provenance

Identity data are taken from the PubChem record for CID 9941957 and its synonym list [11]. Monoisotopic mass and the calculated m/z values are derived arithmetically from the molecular formula in that record and are labelled as calculated. Presentation, fill mass and SKU are taken from the NovoVita catalogue entry for BC10. Storage and degradation statements are general peptide-handling facts supported by references 7 and 8, and are not compound-specific stability data.

Last reviewed 8 August 2026 — first publication of this entry.

Availability